Nexstim Plc: Invitation to the Annual General Meeting

Company announcement, Helsinki, 6 March 2026 at 4:15 PM (EET) 

Nexstim Plc: Invitation to the Annual General Meeting

Nexstim Plc (“Nexstim” or “Company”) is pleased to invite shareholders to the Annual General Meeting of the Company on March 30, 2026 commencing at 10:00 am (EEST) at Nexstim’s head office, Elimäenkatu 9 B (courtyard), 4th floor, 00510 Helsinki. The reception of persons who have registered for the meeting will commence at 9:30 am.

A. Matters on the agenda of the Annual General Meeting of Shareholders

At the Annual General Meeting of Shareholders, the following matters will be considered:

1 OPENING THE MEETING

2 CALLING THE MEETING TO ORDER

3 ELECTION OF THE PERSONS TO SCRUTINISE THE MINUTES AND TO SUPERVISE THE COUNTING OF VOTES

4 ESTABLISHING THE LEGALITY OF THE MEETING

5 RECORDING THE ATTENDANCE AT THE MEETING AND CONFIRMATION OF THE VOTING LIST

6 PRESENTATION OF THE ANNUAL ACCOUNTS INCLUDING CONSOLIDATED ACCOUNTS, THE REPORT OF THE BOARD OF DIRECTORS AND THE AUDITOR'S REPORT FOR YEAR 2025

Review by the CEO

7 ADOPTION OF THE ANNUAL ACCOUNTS AND THE CONSOLIDATED ACCOUNTS

8 PROFIT OF THE FINANCIAL YEAR

The Board of Directors proposes to the Annual General Meeting that no dividend be paid for the financial period 1 Jan – 31 Dec 2025 and that the result for the financial year be recorded in the retained earnings account.

9 DISCHARGING THE MEMBERS OF THE BOARD OF DIRECTORS AND THE CEO FROM LIABILITY

10 RESOLUTION ON THE NUMBER OF MEMBERS OF THE BOARD OF DIRECTORS

The Nomination Board of Shareholders (“Nomination Board”) representing the largest shareholders proposes to the Annual General Meeting that the Board shall have four (4) members.

11 ELECTION OF THE CHAIR AND THE MEMBERS OF THE BOARD OF DIRECTORS

The Nomination Board proposes to the Annual General Meeting that:

• in accordance with their consents to serving on the Board, Martin Forss, Leena Niemistö, Tero Weckroth and Timo Hildén shall be re-elected as members of the Board
• Leena Niemistö is elected as Chair of the Board.

Leena Niemistö is independent of the Company but not independent of the Company’s major shareholders due to the fact that she, together with Kaikarhenni Oy, a company controlled by Ms. Niemistö, together hold approximately 15.04% (on 28 January 2026) of all registered shares and voting rights of the Company. Other proposed members of the Board are independent of the Company and its major shareholders.

The mutual view of the Nomination Board is that the entire Board are suitable for the roles individually and collectively, and Leena Niemistö is suitable to act as the Chair of the Board.

12 RESOLUTION ON THE REMUNERATION OF THE MEMBERS OF THE BOARD OF DIRECTORS AND REIMBURSEMENT OF TRAVEL EXPENSES

The Nomination Board proposes to the Annual General Meeting that the members of the Board of Directors chosen in the Annual General Meeting be remunerated for the period ending at Annual General Meeting 2027 as follows:

• €36,000 for the Chair of the Board of Directors;
• €25,200 for other members;
• That no member of the Board of Directors acting in the Nomination Board of the Shareholders shall receive any fees based on such membership;
• That a member of the Board of Directors will be entitled to remuneration only for the period during which he/she is working as a member of the Board of Directors;
• That a restricted share reward plan be established for the members of the Board of Directors elected to Nexstim Oyj’s Board of Directors for the earning period 2026–2027 under terms that are in principle similar to the share-based reward plans previously applied by the Company, and that the more detailed terms of the arrangement will be published on the Company’s website well in advance of the Annual General Meeting; that the target group of the restricted share reward plan shall consist of members of the Board of Directors who are independent of the Company. However, the target group member does not have to be independent of the Company's shareholders; and
• That the amount of the remunerations for year 2026 will be determined in euro.

It is proposed that according to the Company’s policy, the cash remuneration is paid in four instalments.

The purpose of the restricted share reward plan is to commit the participants to the Company, to align the objectives of the shareholders and the participants and thereby increase the value of the Company, as well as to offer the participants a reward plan based on receiving and earning shares in the Company.

Share rewards payable to the members of the Board of Directors for the earning period 2026–2027

The Nomination Board proposes to the Annual General Meeting that the following gross rewards be paid to the members of the Board of Directors for the earning period 2026–2027:

• Chair of the Board: EUR 24,000
• Member of the Board: EUR 16,800

The granted reward will be converted into share units at the beginning of the earning period in 2026. The conversion of the granted reward into share units will be based on the volume-weighted average price of the Company’s share on Nasdaq Helsinki during the twenty (20) trading days following the publication date of the Company’s financial statements for the financial year 2025. In the plan, one share unit corresponds to one share in the Company. The monetary value of the reward will be determined based on the share price in force on the registration date of the shares paid as reward.

The Nomination Board proposes to the Annual General Meeting that the rewards under the plan be paid to the members of the Board of Directors in the Company’s shares within one month after the Annual General Meeting 2027. If a member of the Board of Directors ceases to serve as a member of the Board before the end of the earning period, no reward will be paid on this basis.

The Company will withhold applicable taxes and employer’s contributions from the cash portion of the reward in accordance with applicable law.

Ownership recommendation

The Nomination Board proposes that,

• the General meeting of Shareholders recommends that the members of the Board of Directors hold shares given as reward as long as their mandate as a member of the Board of Directors continues.

Travelling expenses

In addition, the Nomination Board proposes that,

• reasonable travel expenses are reimbursed against receipts to the members of the Board of Directors, following the principles of the Company’s travel policy. This applies both to members of the Board of Directors and, to the extent applicable, members of the Board of Directors acting as members of the Nomination Board of the Shareholders.

13 AUTHORISATION OF THE MEMBERS OF THE BOARD OF DIRECTORS

The Board of Directors proposes that the Annual General Meeting resolve that, to the extent that a decision by a member of the Board of Directors or the signing of documents concerns that member’s own earlier granted option rights, such member of the Board of Directors shall have the explicit authorisation granted by the Annual General Meeting to participate in such decisions and to sign the relevant documents, and that any potential conflict of interest shall not prevent the member of the Board of Directors from participating in such decisions and actions. Each member of the Board of Directors shall be authorised to represent themselves and to sign the related documents in connection with the aforementioned actions. The above arrangements shall be implemented in the same manner as the other option series of the Company.

The Board of Directors proposes that the Annual General Meeting authorise the members of the Board of Directors to enter into all necessary agreements, documents and other arrangements related to the exercise, waiver, cancellation against consideration, or other transfer of the option rights granted to them as remuneration for their membership on the Board of Directors, including the signing of the relevant agreements as the holder of the option rights on their own behalf.

14 ELECTION OF AUDITOR

The Board of Directors proposes that PricewaterhouseCoopers Oy, Authorized Public Accountant, which has appointed Authorized Public Accountant Tiina Puukkoniemi as the principal auditor, be elected as the Company’s auditor for the period ending at the end of the next Annual General Meeting. The proposed auditor has given their consent to the election.

15 RESOLUTION ON THE REMUNERATION OF THE AUDITOR

The Board of Directors proposes that the auditor be paid reasonable remuneration in accordance with the invoice approved by the Company.

16 AUTHORISATION TO THE BOARD OF DIRECTORS TO DECIDE ON THE ISSUE OF SHARES AND SPECIAL RIGHTS ENTITLING TO SHARES

The Board of Directors proposes to the Annual General Meeting that the Board of Directors be authorized to decide on (i) the issuance of new shares and/or (ii) the transfer of the Company’s own shares and/or (iii) the issuance of special rights referred to in Chapter 10, Section 1 of the Companies Act with the following terms:

Right to shares:

New shares may be issued and the Company’s own shares transferred

• to the Company's shareholders in proportion to their current shareholdings in the Company; or
• deviating from the shareholders' pre-emptive right through one or more directed share issue, if the Company has a weighty financial reason to do so, such as the use of shares as consideration for possible acquisitions or other arrangements related to the company's business or financing of investments.

The new shares can also be issued to the Company itself free of charge. Share issue against payment and without payment: New shares may be issued and treasury shares held by the Company may be transferred either against payment (Share issue against payment) or free of charge (Share issue without payment). A directed share issue can only be without payment if there is a very serious financial reason for it from the Company’s point of view and taking into account the interests of all its shareholders.

Maximum number of shares:

Pursuant to the authorisation, the Board of Directors is entitled to decide on the issuance of new shares and/or the transfer of the Company’s own shares so that the total number of issued and/or transferred shares does not exceed 1,400,000 shares, which corresponds to approximately 16.25 percent of all the shares in the Company after the share issue, provided that new shares are issued, considering all registered shares of the Company.

Issuance of special rights:

The Board of Directors may issue special rights referred to in Chapter 10, Section 1 of the Companies Act, which entitle the holder to receive new shares or the Company’s own shares against payment. The right may also be granted to the Company’s creditor in such a way that the right is subject to the condition that the creditor’s claim is used to set off the share subscription price (convertible bond).

The number of new shares to be subscribed to under the special rights granted by the Company and the number of treasury shares to be transferred held by the Company may not exceed a total of 1,400,000, which is included in the maximum number mentioned in the “Maximum number of shares” -section above.

Recording of the subscription price in the balance sheet:

The subscription price of the new shares and the amount to be paid for the Company’s own shares must be entered in the invested unrestricted equity fund.

Other terms and validity:

The Board of Directors decides on all other matters related to the authorizations.

The authorizations are valid until the next Annual General Meeting from the date of decision of this Annual General Meeting

17 AUTHORISATION REGARDING THE LONG-TERM INCENTIVE PLANS FOR THE MEMBERS OF THE BOARD OF DIRECTORS, MANAGEMENT AND THE PERSONNEL OF THE COMPANY

The Board of Directors proposes to the Annual General Meeting that the Board of Directors be authorized to decide on (i) the issuance of new shares and/or (ii) the conveyance of the Company's own shares held by the Company and/or (iii) the issuance of special rights referred to in Chapter 10, Section 1 of the Companies Act on the following terms and conditions:

The shares issued under the authorization are new shares or treasury shares in the Company's possession. Based and within the limits of this authorization, the Board of Directors can also decide on issuance(s) of option rights or other special rights set forth in Chapter 10 of the Companies Act complementing or replacing issuance(s) of shares. New shares can also be issued as a free share issue to the Company itself.

Share issue against payment and without payment:

New shares can be issued and the Company's own shares can be transferred either against payment (paid share issue) or without payment (free share issue). A directed share issue can only be free of charge if there is a very serious financial reason for it from the Company's point of view and taking into account the interests of all its shareholders.

Under the authorization, a maximum of 130,000 shares may be issued, which corresponds to approximately 1.77 percent of all the shares in the Company after the share issue, provided that new shares are issued, considering all registered shares of the Company.

The shares, option rights and/or other special rights entitling to shares can be issued in one or more tranches. The Board of Directors is authorized to resolve on all terms for the share issues and the terms for the granting of the option rights and other special rights entitling to shares.

The Board of Directors is authorized to resolve on a directed share issue and issue of the special rights entitling to shares in deviation from the shareholders’ pre-emptive right, provided that there is a serious financial reason for the Company to do so.

The authorization is valid for five (5) years from the decision of the Annual General Meeting of Shareholders. The authorization may be used for the implementation of long-term incentive plans for the members of the Board of Directors, management and the personnel of the Company. The authorization can also be used for incentive arrangements and payment of the Board fees.

Authorizations do not revoke previously granted and registered authorizations on the issuance of shares and the issuance of special rights entitling to shares or issuance of option rights.

18 CLOSING THE MEETING

B. Documents of the Annual General Meeting of Shareholders

This invitation to the Annual General Meeting, which includes the proposals made to the Annual

General Meeting, is available on Nexstim Plc’s website at https://nexstim.com/investors/shareholder-meetings/ as well as at the Company’s head office. The Annual accounts, Consolidated accounts, report of the Board of Directors and Auditor’s report are available on the abovementioned website no later than 9 March 2026. The minutes of the Annual General Meeting are available in the abovementioned website no later than 13 April 2026.

C. Instructions for the participants of the Annual General Meeting of Shareholders

1. Shareholders registered in the shareholder register

Each shareholder registered on 18 March 2026 in the shareholders’ register of Nexstim maintained by Euroclear Finland Ltd has the right to participate in the Annual General Meeting of Shareholders. A shareholder whose shares are registered on their personal book-entry account is registered in the shareholders’ register of Nexstim.

A shareholder, who wants to participate in the Annual General Meeting of Shareholders, shall register for the meeting no later than March 26, 2026 at 10:00 a.m. by giving a prior notice of participation. Such notice can be given:

• on the Company’s website: https://nexstim.com/investors/shareholder-meetings/; or
• by mail to address Nexstim Plc, “Annual General Meeting” Elimäenkatu 9B, 00510 Helsinki, Finland.

In connection with the registration, a shareholder shall notify his/her name, personal identification number or business ID, address, telephone number and the name of a possible assistant or proxy representative. The personal data given to Nexstim Plc is used only in connection with the General Meeting of Shareholders and with the processing of related registrations.

2. Holders of nominee registered shares

A holder of nominee registered shares has the right to participate in the Annual General Meeting by virtue of such shares, based on which he/she on the record date of the Annual General Meeting, i.e. on March 18, 2026, would be entitled to be registered in the shareholders’ register of the Company held by Euroclear Finland Ltd. The right to participate in the General Meeting requires, in addition, that the shareholder on the basis of such shares has been registered into the temporary shareholders’ register held by Euroclear Finland Ltd at the latest by March 25, 2026 at 10:00 a.m (EET). As regards nominee registered shares this constitutes due registration for the General Meeting.

A holder of nominee registered shares is advised to request without delay necessary instructions regarding the registration in the shareholders’ register of the Company, the issuing of proxy documents and registration for the General Meeting of Shareholders from his/her custodian bank. The account management organization of the custodian bank has to register a holder of nominee registered shares, who wants to participate in the General Meeting, into the temporary shareholders’ register of the Company at the latest by the time stated above.

3. Proxy representative and powers of attorney

A shareholder may participate in the Annual General Meeting of Shareholders and exercise his/her rights at the Meeting by way of proxy representation.

A proxy representative shall produce a dated proxy document or otherwise in a reliable manner demonstrate his/her right to represent the shareholder at the Annual General Meeting of Shareholders.

When a shareholder participates in the Annual General Meeting of Shareholders by means of several proxy representatives representing the shareholder with shares at different securities accounts, the shares by which each proxy representative represents the shareholder shall be identified in connection with the registration for the Annual General Meeting of Shareholders. Possible proxy documents shall be delivered in originals to Nexstim Plc, “Annual General Meeting” Elimäenkatu 9 B, 00510 Helsinki, Finland before the last date for registration.

4. Other instructions and information

Pursuant to chapter 5, section 25 of the Companies Act, a shareholder who is present at the General Meeting has the right to request information with respect to the matters to be considered at the Meeting.

The meeting will be conducted in Finnish language. Part of the material presented at the meeting will be in the English language.

On the date of this notice to the Annual General Meeting of Shareholders, dated March 6, 2026, the total number of shares and votes in Nexstim Plc is 7,213,387.

Helsinki on 6 March 2026

NEXSTIM PLC

Board of Directors

Further information is available on the website www.nexstim.com, or by contacting: 

Leena Niemistö, Chair of Board of Directors

+358 9 2727 170

leena.niemisto@nexstim.com

The Company’s Certified Adviser is DNB Carnegie Investment Bank AB.

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com